DMYD-B:STO
Diamyd Medical AB
SEK 1,00
arrow_downward
-1,57%(-0,016) 1D
5 Okt., 14:38:51 GMT+2 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMYD-B...
Open
SEK 1,00
High
SEK 1,03
Low
SEK 1,00
Mkt. cap
150,89 m
Avg. vol.
714,91 k
Volume
826,25 k
52-wk high
SEK 17,88
52-wk low
SEK 0,90
EPS
-SEK 1,98
Shares outstanding
134,00 m
No. of employees
44
Open
SEK 1,00
High
SEK 1,03
Low
SEK 1,00
Mkt. cap
150,89 m
Avg. vol.
714,91 k
Volume
826,25 k
52-wk high
SEK 17,88
52-wk low
SEK 0,90
EPS
-SEK 1,98
Shares outstanding
134,00 m
No. of employees
44
News stories
From web sources and news partners
Business Wire
·
41 minute gelede
Powerus (Nasdaq: PUSA) Awarded $82 Million Order for Counter-Unmanned Aerial Systems
GlobeNewswire
·
31 minute gelede
DEEP FISSION, INC. (NASDAQ: FISN) INVESTIGATION: Johnson
Simply Wall Street
·
12 minute gelede
Should Engine Ignition Test Require Action From Kratos (KTOS) Investors?
Yahoo Finance
·
3 uur gelede
Should Direxion NASDAQ-100 Equal Weighted Index ETF (QQQE) Be on Your Investing Radar?
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB